Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma

Ibrutinib, a once‐daily oral inhibitor of Bruton's tyrosine kinase, is approved in the United States and Europe for treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The phase 3 RESONATE study showed improved efficacy of single‐agent ibrutinib ov...

Descripción completa

Detalles Bibliográficos
Autores principales: Munir, Talha, Brown, Jennifer R., O'Brien, Susan, Barrientos, Jacqueline C., Barr, Paul M., Reddy, Nishitha M., Coutre, Steven, Tam, Constantine S., Mulligan, Stephen P., Jaeger, Ulrich, Kipps, Thomas J., Moreno, Carol, Montillo, Marco, Burger, Jan A., Byrd, John C., Hillmen, Peter, Dai, Sandra, Szoke, Anita, Dean, James P., Woyach, Jennifer A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899718/
https://www.ncbi.nlm.nih.gov/pubmed/31512258
http://dx.doi.org/10.1002/ajh.25638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6899718/
https://www.ncbi.nlm.nih.gov/pubmed/31512258
http://dx.doi.org/10.1002/ajh.25638

Ejemplares similares